Researchers discover a drug combination that shrinks tumors in vivo

Sep 27, 2010

Virginia Commonwealth University School of Medicine and VCU Massey Cancer Center researchers have shown that the impotence drug Viagra, in combination with doxorubicin, a powerful anti-cancer drug, enhances its anti-tumor efficacy in prostate cancer while alleviating the damage to the heart at the same time.

For more than four decades the doxorubicin has been used to treat a number of human cancers, including that of the prostate. Despite doxorubicin's clinical efficacy for cancer treatment, its use is associated with irreversible heart damage, often presenting several years after treatment stops. Researchers have been working over the past 15 years to find an optimal therapeutic intervention for protecting the heart against the cytotoxicity associated with doxorubicin.

In the study published online the week of Sept. 27 in the Early Edition of the journal , researchers using a variety of powerful in vitro and in vivo approaches, have shown that a combination of Viagra, generically known as sildenafil, and doxorubcin significantly enhances the generation of reactive oxygen species that trigger cell death, or apoptosis, in . They also observed that the combination did not harm the normal, healthy prostate epithelial cells.

"We believe sildenafil could be an excellent candidate for incorporation into cancer treatment protocols - with the potential of enhancing the anti-tumor efficacy, while protecting the heart against both short term and long term damage from doxorubicin," said principal investigator Rakesh C. Kukreja, Ph.D., scientific director of the VCU Pauley Heart Center and the Eric Lipman professor in cardiology in the VCU School of Medicine, and Anindita Das, Ph.D., assistant professor in the Department of Internal Medicine the VCU School of Medicine.

Kukreja is excited about the potential translational impact of this work. "My team and I are hoping to move the research forward to a clinical trial and plans are under way to do so," he said. The clinical trial would evaluate the effectiveness of the drug combination in cancer patients.

Kukreja's laboratory is one of the first to explore the area of preconditioning. This preconditioning effect was modeled in his lab by "pretreating" mice with doses of sildenafil which also increases therapeutic levels of nitric oxide in the heart.

A preconditioned or pretreated heart has an improved ability to produce nitric oxide and directly improves a patient's outcome following a heart attack. Generally, damage following a heart attack is related to an inability to recover from lack of oxygen.

Explore further: Anal, throat cancers on the rise among young adults, study finds

Related Stories

Potential new therapeutic molecular target to fight cancer

Nov 01, 2007

Researchers at the Virginia Commonwealth University Massey Cancer Center have identified the enzyme sphingosine kinase 2 as a possible new therapeutic target to improve the efficacy of chemotherapy for colon and breast cancer.

Researchers identify genes linked to chemoresistance

Jul 20, 2009

Two genes may contribute to chemotherapy resistance in drugs like 5-fluorouracil, which is used in liver cancer treatment, according to Virginia Commonwealth University Massey Cancer Center researchers.

Recommended for you

Study shows epigenetic changes can drive cancer

10 hours ago

Cancer has long been thought to be primarily a genetic disease, but in recent decades scientists have come to believe that epigenetic changes – which don't change the DNA sequence but how it is 'read' – also play a role ...

Clearing cells to prevent cervical cancer

Jul 25, 2014

A study published online in the International Journal of Cancer earlier this month describes a novel approach to preventing cervical cancer based on findings showing successful reduction in the risk of cervical cancer after ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

robbor
5 / 5 (1) Sep 27, 2010
so, will erections last longer than 4 hours?